PNU-100480 clinical trials
Also written PNU-100480 and Sutezolid.
Its developmentBy Sequella, Bial - Portela C and AJU Pharm, step by step5 company-led studies, furthest phase 2: when each phase was reached, its deals, target and what is ahead.How each study uses PNU-100480 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the PNU-100480 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2009 (2)
| Year | Studies |
|---|---|
| 2009 | 2 |
| 2011 | 1 |
| 2013 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 5
Sequella, Inc. (3) · The Aurum Institute NPC (1) · Indiana University (1) · Bial - Portela C S.A. (1) · Michael Hoelscher (1) · AJU Pharm Co., Ltd. (1) · Global Alliance for TB Drug Development (1) · Pfizer (1)
Often tested with
Tested in the same studies.
Pretomanid (2) · Bedaquiline (2) · Linezolid (2) · Acetylcysteine (1) · Zamicastat (1) · Furosemide (1) · Moxifloxacin (1) · TBI-223 (1)
Studies
Open first, then newest update. How each study uses PNU-100480 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- Bioepuivalence Study for the Safety and the Pharmacokinetics of DWJ1589 and DWC202315Not yet recruitingPhase 1Daewoong Pharmaceutical Co. LTD.NCT06592495Written as Period 3How we know
- Trial of Novel Regimens for the Treatment of Pulmonary TuberculosisSuspendedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT06192160Written as SutezolidHow we know
- Drug-gene-nutraceutical Interactions of Cannabidiol and TacrolimusCompletedPhase 1Indiana UniversityNCT05490511Written as Epidiolex steady-state and tacrolimus single doseHow we know
- Pharmacokinetics, Safety and Tolerability of Concurrent Doses of BIA 5-1058 and FurosemideCompletedPhase 1Bial - Portela C S.A.NCT07173738Written as BIA 5-1058 and FurosemideHow we know
- A Pan-TB Regimen Targeting Host and MicrobeActive, not recruitingPhase 2/3The Aurum Institute NPCNCT05686356Written as SutezolidHow we know
- PanACEA Sutezolid Dose-finding and Combination EvaluationCompletedPhase 2Michael HoelscherNCT03959566Written as SutezolidHow we know
- The Drug-drug Interaction Study of AJU-A51R1 and AJU-A51R2CompletedPhase 1AJU Pharm Co., Ltd.NCT04970940Written as Treatment CHow we know
- Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SutezolidCompletedPhase 1Global Alliance for TB Drug DevelopmentNCT03199313Written as SutezolidHow we know
- PNU-100480 In Newly Diagnosed, Drug Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood AssayCompletedPhase 2Sequella, Inc.NCT01225640Written as PNU-100480How we know
- Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult VolunteersCompletedPhase 1Sequella, Inc.NCT00990990Written as PNU-100480How we know
- Safety, Tolerability And Pharmacokinetics Study Of Single Doses Of PNU-100480 In Healthy AdultsCompletedPhase 1Sequella, Inc.NCT00871949Written as PNU-100480How we know
- A Study To Determine Any Effect Of Tafamidis On Electrocardiographic Intervals, Specifically The Rate Corrected QT Interval (QTc)CompletedPhase 1PfizerNCT01775761Written as Period 3How we know
What changed recently
From the registry's own updates since Oct 20, 2026.
Stopped1
- Trial of Novel Regimens for the Treatment of Pulmonary TuberculosisSuspendedNov 2, 2026NCT06192160